- Home
- DMN vs CGTX Comparison
DMN vs CGTX Comparison
Compare DMN & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMN
- CGTX
- Stock Information
- Founded
- DMN 2020
- CGTX 2007
- Country
- DMN Canada
- CGTX United States
- Employees
- DMN N/A
- CGTX N/A
- Industry
- DMN
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- DMN
- CGTX Health Care
- Exchange
- DMN NYSE
- CGTX Nasdaq
- Market Cap
- DMN 19.4M
- CGTX 16.1M
- IPO Year
- DMN N/A
- CGTX 2021
- Fundamental
- Price
- DMN $0.73
- CGTX $0.68
- Analyst Decision
- DMN
- CGTX Strong Buy
- Analyst Count
- DMN 0
- CGTX 6
- Target Price
- DMN N/A
- CGTX $8.30
- AVG Volume (30 Days)
- DMN 442.1K
- CGTX 18.9M
- Earning Date
- DMN 02-15-2025
- CGTX 11-13-2024
- Dividend Yield
- DMN N/A
- CGTX N/A
- EPS Growth
- DMN N/A
- CGTX N/A
- EPS
- DMN N/A
- CGTX N/A
- Revenue
- DMN N/A
- CGTX N/A
- Revenue This Year
- DMN N/A
- CGTX N/A
- Revenue Next Year
- DMN N/A
- CGTX N/A
- P/E Ratio
- DMN N/A
- CGTX N/A
- Revenue Growth
- DMN N/A
- CGTX N/A
- 52 Week Low
- DMN $0.51
- CGTX $0.34
- 52 Week High
- DMN $4.95
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- DMN N/A
- CGTX 51.83
- Support Level
- DMN N/A
- CGTX $0.67
- Resistance Level
- DMN N/A
- CGTX $0.76
- Average True Range (ATR)
- DMN 0.00
- CGTX 0.08
- MACD
- DMN 0.00
- CGTX -0.02
- Stochastic Oscillator
- DMN 0.00
- CGTX 9.12
About DMN DAMON INC
Damon Inc is a motorcycle manufacturing company that aims to transform the motorcycle industry by building a smart and technologically advanced motorcycle. Damon is developing technology and investing in capabilities to lead the industry in the transformation of the high-performance electric motorcycle market. It is introducing existing enthusiasts to high-performance electric products while bringing new riders to the motorcycle community with first-of-its-kind advances in zero-emissions motorcycle performance, safety, connectivity and AI.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.